Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Liankang Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4980-8460; OpenAlex author ID A5101076617. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2016: 1 paper · 2017: 4 papers · 2018: 4 papers · 2019: 4 papers · 2020: 2 papers

Papers 15

  1. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  2. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor‑stromal crosstalk under hypoxic conditions via the IL‑6/ERK/NF‑κB axis. First author DOI 10.3892/or.2020.7600↗
  3. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Co-author DOI 10.1002/1878-0261.12399↗
  4. Knockdown of KDM1B inhibits cell proliferation and induces apoptosis of pancreatic cancer cells. First author DOI 10.1016/j.prp.2019.02.014↗
  5. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Co-author DOI 10.1111/cpr.12514↗
  6. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  7. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  8. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Co-author DOI 10.1016/j.yexcr.2018.07.041↗
  9. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Co-author DOI 10.1155/2018/9482018↗
  10. Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-β/SMAD2/3 signaling. Co-author DOI 10.3892/or.2018.6281↗
  11. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Co-author DOI 10.1002/1878-0261.12116↗
  12. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  13. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Co-author DOI 10.1186/s12943-017-0701-0↗
  14. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  15. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Co-author DOI 10.3390/nu8100546↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 14 shared papers, 2016–2020 · strength 1.06
  2. Wanxing Duan · 11 shared papers, 2016–2020 · strength 0.78
  3. Weikun Qian · 10 shared papers, 2017–2020 · strength 0.76
  4. Jiguang Ma · 10 shared papers, 2016–2020 · strength 0.72
  5. Ke Chen · 9 shared papers, 2016–2019 · strength 0.63
  6. Cancan Zhou · 9 shared papers, 2016–2019 · strength 0.61
  7. Zhengdong Jiang · 9 shared papers, 2016–2019 · strength 0.59
  8. Junyu Cao · 8 shared papers, 2017–2019 · strength 0.58
  9. Liang Cheng · 8 shared papers, 2017–2019 · strength 0.57
  10. Jie Li · 7 shared papers, 2017–2020 · strength 0.52
  11. Jianjun Lei · 6 shared papers, 2017–2020 · strength 0.51
  12. Zheng Wang · 6 shared papers, 2016–2020 · strength 0.48
  13. Bin Yan · 6 shared papers, 2017–2019 · strength 0.43
  14. Qinhong Xu · 5 shared papers, 2017–2020 · strength 0.37
  15. Xuqi Li · 4 shared papers, 2017–2020 · strength 0.30
  16. Erxi Wu · 4 shared papers, 2017–2019 · strength 0.28
  17. Zheng Wu · 3 shared papers, 2017–2020 · strength 0.27
  18. Ying Xiao · 2 shared papers, 2019–2020 · strength 0.19
  19. Liang Han · 2 shared papers, 2018–2019 · strength 0.15
  20. Tao Qin · 2 shared papers, 2018–2019 · strength 0.15
  21. Shuixiang He · 1 shared paper, 2019 · strength 0.14
  22. Yun Wang · 1 shared paper, 2019 · strength 0.14
  23. Wěi Li · 1 shared paper, 2020 · strength 0.13
  24. Liang Han · 2 shared papers, 2017 · strength 0.11
  25. Zhenhua Ma · 2 shared papers, 2017 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.